158 related articles for article (PubMed ID: 23634556)
1. [Metastatic colorectal carcinoma: bevacizumab extends total survival].
Pflege Z; 2013 Apr; 66(4):252. PubMed ID: 23634556
[No Abstract] [Full Text] [Related]
2. [Improving longevity in advanced intestinal cancer].
Schmoll HJ
Krankenpfl J; 2005; 43(1-3):48. PubMed ID: 15912837
[No Abstract] [Full Text] [Related]
3. Bevacizumab in the treatment of metastatic colorectal cancer.
Caprioni F; Fornarini G
Future Oncol; 2007 Apr; 3(2):141-8. PubMed ID: 17381413
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab in colorectal cancer: current and future directions.
Yeung Y; Tebbutt NC
Expert Rev Anticancer Ther; 2012 Oct; 12(10):1263-73. PubMed ID: 23113577
[TBL] [Abstract][Full Text] [Related]
5. Progression-free survival in bevacizumab-based first-line treatment for patients with metastatic colorectal cancer: is it a really good end point?
Montagnani F; Migali C; Fiorentini G
J Clin Oncol; 2009 Oct; 27(28):e132-3; author reply e134-5. PubMed ID: 19720898
[No Abstract] [Full Text] [Related]
6. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
Shih T; Lindley C
Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
[TBL] [Abstract][Full Text] [Related]
7. Use of bevacizumab in the treatment of metastatic colorectal cancer.
Raouf S; Bridgewater J; Ellis R; Ferry D; Hill M; Wasan H
Br J Hosp Med (Lond); 2012 Jan; 73(1):25-30. PubMed ID: 22241406
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapy in colorectal carcinoma: more than a theory.
Pickering L; Rudman S; Ross PJ; Leslie MD
Colorectal Dis; 2008 Mar; 10(3):209-18; discussion 218-221. PubMed ID: 18257846
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer.
Whyte S; Pandor A; Stevenson M; Rees A
Health Technol Assess; 2010 Oct; 14(Suppl. 2):47-53. PubMed ID: 21047491
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study.
Kozloff M; Yood MU; Berlin J; Flynn PJ; Kabbinavar FF; Purdie DM; Ashby MA; Dong W; Sugrue MM; Grothey A;
Oncologist; 2009 Sep; 14(9):862-70. PubMed ID: 19726453
[TBL] [Abstract][Full Text] [Related]
11. Phase III multicenter randomized clinical trial to evaluate the safety and efficacy of CoFactor/5-fluorouracil/bevacizumab versus leucovorin/5-fluorouracil/bevacizumab as initial treatment for metastatic colorectal carcinoma.
Saif MW; Merritt J; Robbins J; Stewart J; Schupp J
Clin Colorectal Cancer; 2006 Sep; 6(3):229-34. PubMed ID: 17026795
[No Abstract] [Full Text] [Related]
12. Antiangiogenesis research is booming, as questions and studies proliferate.
Brower V
J Natl Cancer Inst; 2009 Jun; 101(11):780-1. PubMed ID: 19470957
[No Abstract] [Full Text] [Related]
13. The use of high dose d,l-leucovorin in first-line bevacizumab+mFOLFIRI treatment of patients with metastatic colorectal cancer may enhance the antiangiogenic effect of bevacizumab.
Budai B; Nagy T; Láng I; Hitre E
Angiogenesis; 2013 Jan; 16(1):113-21. PubMed ID: 22956187
[TBL] [Abstract][Full Text] [Related]
14. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer.
Los M; Roodhart JM; Voest EE
Oncologist; 2007 Apr; 12(4):443-50. PubMed ID: 17470687
[TBL] [Abstract][Full Text] [Related]
15. Unusual ischemic complication of bevacizumab treatment for metastatic colorectal carcinoma.
Ryan EM; Hanly A; Morrin MM; McNamara DA
J Clin Oncol; 2013 Oct; 31(30):e433-4. PubMed ID: 23775957
[No Abstract] [Full Text] [Related]
16. Bevacizumab in HIV-positive patients: concerns about safety and potential for therapeutic use.
Magné N; Chargari C; Levy A; Guy JB; Merrouche Y; Spano JP
J Chemother; 2014 Aug; 26(4):253-5. PubMed ID: 24090564
[TBL] [Abstract][Full Text] [Related]
17. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E
J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961
[TBL] [Abstract][Full Text] [Related]
18. Tenth anniversary of bevacizumab in colorectal cancer: has it fulfilled its promise?
Salazar R; Grasselli J; Santos C; Tabernero J
Future Oncol; 2014 Feb; 10(2):149-52. PubMed ID: 24490598
[No Abstract] [Full Text] [Related]
19. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer.
Ferrara N; Hillan KJ; Gerber HP; Novotny W
Nat Rev Drug Discov; 2004 May; 3(5):391-400. PubMed ID: 15136787
[No Abstract] [Full Text] [Related]
20. Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer.
Dohn LH; Jensen BV; Larsen FO
Acta Oncol; 2010 Apr; 49(3):395-6. PubMed ID: 20001495
[No Abstract] [Full Text] [Related]
[Next] [New Search]
